Impact of Rechallenge with Imatinib in Patients with Advanced Gastrointestinal Stromal Tumor after Failure of Imatinib and Sunitinib
Joint Authors
Sawaki, Akira
Nishida, Toshirou
Komatsu, Yoshito
Kanda, Tatsuo
Source
Gastroenterology Research and Practice
Issue
Vol. 2014, Issue 2014 (31 Dec. 2014), pp.1-6, 6 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2014-01-22
Country of Publication
Egypt
No. of Pages
6
Main Subjects
Abstract EN
Purpose.
This retrospective, nonrandomized study investigated the effect of imatinib rechallenge plus best supportive care (BSC) on overall survival after imatinib and sunitinib treatment for patients with locally advanced or metastatic gastrointestinal stromal tumor (GIST).
Methods.
Twenty-six patients who had previously been exposed to both imatinib and sunitinib were enrolled in this study.
The treatment regimen was BSC with or without imatinib, based on the patient’s choice after discussion with his or her physician.
The primary endpoint was overall survival, and secondary endpoints were time to treatment failure, clinical response rate assessed by Choi criteria, and safety.
Results.
Fourteen patients were treated with imatinib plus BSC and 12 received BSC alone.
Median overall survival was greatly improved for the imatinib group, although differences were not significant (22 months for imatinib plus BSC versus 4 months for BSC; P=0.058).
Three patients (21%) had a clinical response in the imatinib group, and one had a clinical response in the BSC alone group.
Imatinib was well tolerated.
Conclusions.
Rechallenge with imatinib may be associated with improvement in overall survival without deteriorating performance status in patients who failed imatinib and sunitinib.
A prospective study should be considered to confirm the efficacy of rechallenge with imatinib.
American Psychological Association (APA)
Sawaki, Akira& Kanda, Tatsuo& Komatsu, Yoshito& Nishida, Toshirou. 2014. Impact of Rechallenge with Imatinib in Patients with Advanced Gastrointestinal Stromal Tumor after Failure of Imatinib and Sunitinib. Gastroenterology Research and Practice،Vol. 2014, no. 2014, pp.1-6.
https://search.emarefa.net/detail/BIM-464378
Modern Language Association (MLA)
Sawaki, Akira…[et al.]. Impact of Rechallenge with Imatinib in Patients with Advanced Gastrointestinal Stromal Tumor after Failure of Imatinib and Sunitinib. Gastroenterology Research and Practice No. 2014 (2014), pp.1-6.
https://search.emarefa.net/detail/BIM-464378
American Medical Association (AMA)
Sawaki, Akira& Kanda, Tatsuo& Komatsu, Yoshito& Nishida, Toshirou. Impact of Rechallenge with Imatinib in Patients with Advanced Gastrointestinal Stromal Tumor after Failure of Imatinib and Sunitinib. Gastroenterology Research and Practice. 2014. Vol. 2014, no. 2014, pp.1-6.
https://search.emarefa.net/detail/BIM-464378
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-464378